Soluble CD163

  title={Soluble CD163},
  author={Holger Jon M{\o}ller},
  journal={Scandinavian Journal of Clinical and Laboratory Investigation},
  pages={1 - 13}
  • H. Møller
  • Published 1 February 2012
  • Biology, Medicine
  • Scandinavian Journal of Clinical and Laboratory Investigation
Abstract CD163 is an endocytic receptor for haptoglobin-hemoglobin complexes and is expressed solely on macrophages and monocytes. As a result of ectodomain shedding, the extracellular portion of CD163 circulates in blood as a soluble protein (sCD163) at 0.7–3.9 mg/l in healthy individuals. The function of sCD163 is unknown, but during inflammation and macrophage activation, sCD163 levels increase acutely due to metalloproteinase-mediated cleavage near the cell membrane. It is now evident that… 
CD163 and inflammation: biological, diagnostic, and therapeutic aspects.
The scavenging of the oxidative and proinflammatory Hb leading to stimulation of the heme-oxygenase-1 and production of anti- inflammatory heme metabolites indicates that CD163 indirectly contributes to the anti-inflammatory response.
Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of ‘soluble CD163’ in plasma
The results show that soluble ectodomain CD163 and EV CD163 in plasma are part of separate macrophage response in the context of systemic inflammation.
Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
Macrophages are essential components of the human host immune system, which upon activation facilitates a broad pallet of immunomodulatory events including release of pro- or anti-inflammatory
Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
In multiple studies sCD163 and sCD206 are elevated in relation to liver disease severity and established as reliable predictors of morbidity and mortality, however, differences in expression- and shedding-stimuli for CD163 and CD206 may explain dissimilarities in prognostic utility in patients with acute decompensation of cirrhosis and ACLF.
Circulating Levels of the Shed Scavenger Receptor sCD163 and Association with Outcome of Critically Ill Patients
Elevated baseline sCD163 levels were independently associated with ICU mortality, liver dysfunction, and time to discharge from ICU and hospital, and may point to the liver as a potential source.
Nonclassical monocytes: are they the next therapeutic targets in multiple sclerosis?
The composition of monocyte subsets and other inflammation-related cellsurface markers in a broad spectrum of MS patients, both treated and nontreated, compared to healthy individuals are examined.
Soluble CD163, a Product of Monocyte/Macrophage Activation, Is Inversely Associated with Haemoglobin Levels in Placental Malaria
Inverse relationships between levels of sCD163 and clinical parameters in women with placental malaria suggest a potential role for monocyte/macrophage activation in the pathogenesis of malaria in pregnancy, particularly in relation to malaria-associated anaemia.
Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology
Monocyte-macrophage activation markers are increased and correlate with other inflammatory markers in SARS-Cov-2 infection, in association to hospital admission, and data suggest a preponderant role for monocytes in the development of immunopathology of COVID-19 patients.
A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness
Levels of sMR are strongly elevated in several disease states, including sepsis and liver disease, and the protein shows promise as a new biomarker, according to an optimised ELISA suitable for quantitative measurements.
Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases
Recent progress in drug-targeting of the surface marker CD163 expressed in a subpopulation of macrophages is described, which has a low toxicity profile that may highly improve the therapeutic window of many current drugs and drug candidates.


Soluble CD163: a marker molecule for monocyte/macrophage activity in disease
The present data suggest that sCD163 might prove to be a valuable marker molecule in infectious and myeloproliferative diseases.
Soluble CD163 inhibits phorbol ester-induced lymphocyte proliferation.
A potential direct anti-inflammatory effect mediated by soluble CD163 is identified and statistically significantly inhibits phorbol ester-induced human T-lymphocyte activation, thus attenuating the immune response to the inflammatory mediator.
Soluble hemoglobin–haptoglobin scavenger receptor CD163 as a lineage‐specific marker in the reactive hemophagocytic syndrome
Serum levels of the macrophage specific scavenger receptor CD163 were detemined by enzyme‐linked immunosorbent assay (ELISA) and were found to be highly increased in patients with RHS and close correlations of sCD163 with clinical disease activity, serum ferritin and other markers of macrophages activity were revealed.
In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis.
It is suggested that neutrophil elastase promotes CD163 shedding, resulting in a decreased clearance of Hb by macrophages, which may favour plaque destabilization.
Levels of Soluble CD163 and Severity of Malaria in Children in Ghana
The study showed that sCD163 levels are elevated during acute malaria, and this may be due to the induction of higher-level anti-inflammatory responses, enabling them to avoid disease complications.
Tumor necrosis factor α‐converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163
The present results provide a likely explanation for the strong empirical relationship between the sCD163 plasma level and infectious/inflammatory diseases relating to macrophage activity.
Endotoxin induces rapid metalloproteinase‐mediated shedding followed by up‐regulation of the monocyte hemoglobin scavenger receptor CD163
It is shown that CD163 is rapidly mobilized in response to bacterial endotoxin, and studies using the inhibitor TAPI‐0 indicate that a metalloproteinase is responsible for LPS‐mediated shedding of CD163.